CG Oncology | IPO Presentation Deck | 45 slides

Slide schematic 6/6

diagram 1/1 disclaimer 1/1 list 3/3 title 1/1

Components 6

process disclaimer bullet bullet bullet headline

Tools 1

list/bullet: Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

PIVOT-006 trial design slide.